Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCAR-G08 in Advanced Gastrointestinal Tumors
NCT06197178Phase 1Terminated
- Sponsor
- Peking University
- Start
- Dec 2023
- Primary completion
- Oct 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LCAR-G08 cells in gastrointestinal tumor, colorectal cancer (CRC), esophageal cancer and 3 more, sponsored by Peking University. Primary endpoints: Dose-limiting toxicity rate at 2 years, Treatment-emergent adverse events at 2 years and 5 more. Started Dec 2023; status: terminated.
02
Drugs
LCAR-G08 cells
03
Conditions
gastrointestinal tumorcolorectal cancer (CRC)esophageal cancergastric cancer (GC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06197178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06197178.